Video

Tim Turnham Discusses Melanoma Treatment Advances

Author(s):

Tim Turnham, PhD
Conference|ASCO Annual Meeting

Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances

Tim Turnham, PhD, the Executive Director of the Melanoma Research Foundation (MRF) Discusses Melanoma Treatment Advances

Related Videos
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Manali Kamdar, MD
Ibrahim Aldoss, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Related Content
Michael Wang, MD, of The University of Texas MD Anderson Cancer Center
June 17th 2024

Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Suzanne Lentzsch, MD, PhD, professor, clinical medicine, director, Multiple Myeloma and Amyloidosis Program, College of Physicians and Surgeons, Columbia University Medical Center and NewYork-Presbyterian Hospital
June 17th 2024

Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Jing-Zhou Hou, MD, PhD, of UPMC Hillman Cancer Center
June 17th 2024

Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes

William Wierda, MD, PhD
June 17th 2024

Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL